XOMA Royalty (XOMA) Cash from Operations (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Cash from Operations came in at 6121000.0 in Q1 2026, up 178.48% year-on-year from 2198000.0 in Q1 2025, and up 211.27% quarter-over-quarter from 5501000.0 in Q4 2025.
XOMA Royalty (XOMA) Cash from Operations (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Cash from Operations across 17 years of filings, most recently posting 6121000.0 for Q1 2026.
- Cash from Operations for Q1 2026 came in at 6121000.0, up 178.48% year-over-year; the trailing twelve-month figure through Mar 2026 was 6794000.0 (up 202.89% YoY), and the FY2025 annual result was 2871000.0, up 120.88% from the prior year.
- Cash from Operations came in at 6121000.0 for Q1 2026 at XOMA Royalty, up from 5501000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 6470000.0 in Q2 2025 to a low of 8625000.0 in Q3 2024.
- The 5-year median for Cash from Operations is 3663000.0 (2022), against an average of 2105470.59.
- Across the five-year window, Cash from Operations sank 388.01% in 2023 and surged 178.48% in 2026, its largest moves.
- XOMA Royalty's Cash from Operations stood at 3890000.0 in 2022, then fell by 0.95% to 3927000.0 in 2023, then gained by 26.08% to 2903000.0 in 2024, then slumped by 89.49% to 5501000.0 in 2025, then surged by 211.27% to 6121000.0 in 2026.
- The last three Cash from Operations figures came in at 6121000.0 (Q1 2026), 5501000.0 (Q4 2025), and 296000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 6.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.12 Mn |
| Mar 31, 2026 | 6.12 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Sep 30, 2025 | -296,000.00 |
| Sep 30, 2025 | -296,000.00 |
| Jun 30, 2025 | 6.47 Mn |
| Jun 30, 2025 | 6.47 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Dec 31, 2024 | -2.90 Mn |
| Dec 31, 2024 | -2.90 Mn |
| Sep 30, 2024 | -8.63 Mn |
| Sep 30, 2024 | -8.63 Mn |
| Jun 30, 2024 | 2.73 Mn |
| Jun 30, 2024 | 2.73 Mn |
| Mar 31, 2024 | -4.95 Mn |
| Mar 31, 2024 | -4.95 Mn |
| Dec 31, 2023 | -3.93 Mn |
| Dec 31, 2023 | -3.93 Mn |